MEN2 syndrome

MEN2 (Multiple Endocrine Neoplasia type 2) syndrome is a rare inherited condition causing an increased risk of medullary thyroid cancer, along with tumours of the adrenal glands (phaeochromocytoma) and sometimes the parathyroid glands. Regular screening allows these to be caught and treated early.

It's caused by mutations in the RET gene, inherited in an autosomal dominant pattern, meaning an affected parent has a 50% chance of passing the condition to each child. Different specific mutations within this gene are associated with somewhat different patterns of risk and disease severity.

Symptoms can include a thyroid lump from medullary thyroid cancer, symptoms of adrenal gland overactivity such as high blood pressure, palpitations and sweating from a phaeochromocytoma, and sometimes symptoms related to parathyroid gland overactivity. Many features are identified through proactive screening before symptoms develop, given the known genetic risk.

Yes, medullary thyroid cancer can be aggressive, particularly in certain genetic subtypes, and phaeochromocytoma can cause dangerous blood pressure spikes if undetected, particularly during surgery or childbirth, making proactive surveillance and, in some cases, preventive treatment essential. With appropriate management, most complications can be effectively prevented or treated early.

Yes, it's an inherited genetic condition, and genetic testing can confirm the diagnosis and identify at-risk family members who should undergo testing and, if positive, appropriate surveillance or preventive treatment. Genetic counselling is essential given the significant implications of a MEN2 diagnosis for the whole family.

Yes, preventive removal of the thyroid gland is often recommended for confirmed gene carriers, sometimes in childhood depending on the specific mutation, to prevent medullary thyroid cancer from developing, alongside regular screening and treatment for any adrenal or parathyroid involvement. This proactive approach has significantly improved outcomes for people with MEN2.

Management typically involves genetic testing to confirm the diagnosis and specific mutation, consideration of preventive thyroid surgery timed based on the specific mutation's risk level, and ongoing regular screening for adrenal and parathyroid involvement. A specialist endocrinology and genetics team coordinates this comprehensive, lifelong care.

The timing depends on the specific RET gene mutation identified, with higher-risk mutations sometimes warranting surgery in early childhood, while lower-risk mutations may allow surgery to be delayed with close monitoring instead. Your specialist genetics and endocrinology team will provide individualised guidance based on your specific mutation.

MEN2A is the more common subtype, typically involving medullary thyroid cancer, phaeochromocytoma, and sometimes parathyroid disease, while MEN2B is rarer, tends to cause more aggressive, earlier-onset medullary thyroid cancer, and includes additional distinctive features such as characteristic facial appearance and bowel nerve abnormalities. Genetic testing identifies which specific subtype is present, which significantly affects the urgency of preventive treatment.

A family history of MEN2 or medullary thyroid cancer should prompt genetics and endocrinology referral promptly. Private specialist consultations can typically be arranged within about two weeks, considerably faster than standard NHS waiting times.